Tesla, Inc. (NASDAQ:TSLA) Still Eagerly Entering New Market As Lower Oil Prices Have Dampened Consumer Demand

Tesla, Inc. (NASDAQ:TSLA) [Trend Analysis] retains strong position in active trade, as shares scoring 0.01% to $269.23 in a active trade session, while looking at the shares volume, around 3.62 Million shares have changed hands in this session. Tesla Inc (TSLA) declared that it has started selling its luxury electric cars in Dubai, marking its first foray into the Middle East.Sales of luxury cars in the Gulf States are among highest in the world per capita, although some brands have suffered as lower oil prices have dampened consumer demand.

California-based Tesla is accepting online orders from consumers in the United Arab Emirates, a pop-up store in the Dubai Mall and a Tesla service center being built on Dubai’s Sheikh Zayed Road, which is due to open in July. Founder Elon Musk said on Monday that Tesla will open a store and service center in Abu Dhabi in 2018 and plans to expand to Bahrain, Oman and Saudi Arabia. Musk declined to elaborate on his wider plans or timeline for expansion outside the UAE at a press conference in Dubai. The firm has institutional ownership of 58.90%, while insider ownership included 0.30%. TSLA attains analyst recommendation of 2.90 with week’s performance of 7.12%. Investors looking further ahead will note that the Price to next year’s EPS is 52.40%.

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) [Trend Analysis] swings enthusiastically in regular trading session, it an increase of 2.52% to close at $2.85. VistaGen Therapeutics Inc. (NASDAQ:VTGN) declared financial results for the third quarter of fiscal 2017 ended December 31, 2016. “We are excited about our progress during the last quarter, with several key advances related to our MDD-focused programs for AV-101, as well as potential regenerative medicine and drug rescue applications of our cardiac stem cell technology. Following productive discussions with the FDA last quarter, our team and key advisors have been working diligently to complete the diverse regulatory and technical activities necessary to support the planned launch of our Phase 2b study of AV-101 next quarter, a study we believe has game-changing potential for the millions of patients who battle MDD every day with inadequate therapies,” commented Shawn Singh, Chief Executive Officer of VistaGen.

“Also, our recent sublicense contract with BlueRock Therapeutics was an important advance in our cardiac stem cell program while we remain primarily focused on our Phase 2 programs for AV-101. With potentially catalytic milestones in the coming quarters, we believe we are poised to unlock important value for our shareholders throughout 2017,” added Mr. Singh. The stock is going forward its fifty-two week’s  low with 15.38% and lagging behind from its 52-week’s  high price with -68.33%. VTGN last month stock price volatility remained 8.90%.

 

About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *